Loading…

Blood Targets of Adjuvant Drugs Against COVID19

While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-k...

Full description

Saved in:
Bibliographic Details
Published in:Journal of blood medicine 2020-07, Vol.11, p.237-241
Main Authors: Micco, Pierpaolo Di, Micco, Gianluca Di, Russo, Vincenzo, Poggiano, Maria Rita, Salzano, Ciro, Bosevski, Marijan, Imparato, Michele, Fontanella, Luca, Fontanella, Andrea
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-known drugs such as anticoagulants, antihypertensives, antiserotoninergics and immunomodulants. We here report a basic list of these drugs that include bioflavonoids, heparinoids, ACE inhibitors, angiotensin receptor blockers, antiserotoninergics, and monoclonal antibodies against cytokines that may interact with the viral cycle. Keywords: COVID19, flavonoid, heparin, ace-inhibitors, interleukin, angiotensin receptor blockers
ISSN:1179-2736
1179-2736
DOI:10.2147/JBM.S256121